ArticleClinical rheumatology2025
Post-Chikungunya musculoskeletal symptoms and predictors of chronic inflammatory joint disease, Mato Grosso, Brazil.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterization of the clinical forms of chronic chikungunya: an observational cohort study in Rio de Janeiro.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Observational
- Unveiling Clinical Phenotypes in Chronic Chikungunya Disease: Insights from a Brazilian Observational Study.Tropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify the epidemiological and clinical characteristics of patients with post-Chikungunya chronic inflammatory joint disease.
methodsA cohort study was conducted with 226 patients with post-Chikungunya chronic inflammatory joint disease (pCHIKV-CIJD), treated between July 2017 and January 2023 at the outpatient clinic of the University of Cuiabá, Mato Grosso. Patients were divided into two groups: Group 1 (73 patients presenting improved symptoms in the acute phase) and Group 2 (153 patients with persistent joint symptoms for > 3 months). Epidemiological, clinical, and laboratory data were collected; disease activity was assessed by the Clinical Disease Activity Index (CDAI) during semiannual follow-ups along 24 months.
resultsMost patients were middle-aged women (86.3%, mean 51.1 years of age). Systemic arterial hypertension (hypertension: 26.5% versus 11.0%; p = 0.030) and osteopenia (8.3% versus 0.0%; p = 0.023) were associated with disease chronicity. At baseline visits, patients evolving into chronic disease presented a significantly increased frequency of hypertension, osteopenia, and morning stiffness (p < 0.001-p = 0.010). A progressive reduction in CDAI and the number of painful joints was observed, consistent with an increase in the percentage of patients with clinical improvement over time, which rose from 34.6% in the baseline visit (V1) to 72.5% in V4.
conclusionsFactors such as female gender, middle age, hypertension, osteopenia, and morning stiffness at the acute phase of the disease are predictors of symptom persistence and progression to chronicity. Early therapeutic intervention with continuous clinical follow-up has proven to decrease disease activity over time, reinforcing the importance of proactive management to prevent the progression of pCHIKV-CIJD. Key Points • Female gender, middle age, hypertension, osteopenia, and morning stiffness predict chronic joint symptoms after Chikungunya infection. • Early treatment and regular follow-up reduce disease activity and improve patient's outcomes over time.
Indexed as
Identifiers
41073849What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.